ResearcherAzienda Unità Sanitaria Locale PiacenzaActive in the last 2 years
Andrea Romboli
Matched on ORCID iD 0000-0002-7725-635X; OpenAlex author ID A5053001330. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2024: 1 paper · 2025: 1 paper
Papers 2
- State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. Co-author DOI 10.3390/ijms26062620↗
- Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression-A Scoping… Last author DOI 10.3390/cancers16162912↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elena Orlandi · 2 shared papers, 2024–2025 · strength 0.46
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Paper Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Gro… DOI 10.3390/cancers16162912↗
- Stefano Vecchia · 2 shared papers, 2024–2025 · strength 0.46
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Paper Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Gro… DOI 10.3390/cancers16162912↗
- Mario Giuffrida · 2 shared papers, 2024–2025 · strength 0.46
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Paper Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Gro… DOI 10.3390/cancers16162912↗
- Chiara Citterio · 1 shared paper, 2025 · strength 0.25
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.